$9.78−0.08 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Intellia Therapeutics (NTLA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
20 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~19.6%/yr (FY21→FY25), net margin −609.9%. Worth your attention in FY25: Share count (+52.9%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲16.9%
67.7
FY21→FY25CAGR +19.6%/yr
Net income ($M)▲20.5%
−412.7
FY21→FY25CAGR —
Free cash flow ($M)▼11.6%
−395.9
FY21→FY25CAGR —
Diluted EPS▲27.4%
−3.81
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+52.9%
70.9mn → 108.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$1.1M
−80.5% YoY in FY25 · 1.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-610¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -609.9% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7731, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 52.9 | 67.7 | 57.9 | 36.3 | 52.1 | 33.1 | ▲16.9% | +19.6% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | —A | — | — |
Research & development | 335.3 | 388.9 | 466.3 | 435.1 | 420.0 | 229.8 | ▼16.6% | +14.1% |
Selling, general & admin | 151.9 | 119.8 | 125.8 | 116.5 | 90.3 | 71.1 | ▼4.8% | +13.9% |
Total operating expenses | 487.2 | 508.7 | 592.1 | 551.7 | 510.3 | 300.9 | ▼14.1% | +14.0% |
Operating incomefeeds ROC rank | −434.3 | −441.0 | −534.3 | −515.3 | −458.2 | −267.9 | ▲17.5% | — |
Other income, net | 7.4 | 28.7 | 16.0 | 37.8 | −16.0 | −2.2 | — | — |
Pretax income | −426.9 | −412.3 | −518.3 | −477.5 | −474.2 | −270.1 | ▲20.5% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −426.1 | −412.7 | −519.0 | −481.2 | −474.2 | −267.9 | ▲20.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.33 | −3.81 | −5.25 | −5.42 | −6.16 | −3.78 | ▲27.4% | — |
Diluted shares (mn) | 140.19 | 108.38 | 98.85 | 88.77 | 76.97 | 70.89 | ▲9.6% | +11.2% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | —A | — | — |
Operating margin | −821.2% | −651.7% | −923.1% | −1420.5% | −879.0% | −810.4% | ▲271.4pp | +158.7pp |
Net margin3rd pct in Healthcare | −805.7% | −609.9% | −896.8% | −1326.5% | −909.8% | −810.5% | ▲286.9pp | +200.6pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Intellia Therapeutics' revenue last fiscal year?
Intellia Therapeutics reported revenue of $67.7M in fiscal 2025, up 16.9% from fiscal 2024.
What was Intellia Therapeutics' net income?
Intellia Therapeutics reported net income of −$412.7M in fiscal 2025, a net margin of −609.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

